 Shares of Zymeworks Inc. ZYME, -2.43 gained 8.4 in premarket trading on Wednesday after the company announced a licensing deal with Jazz Pharmaceuticals plc JAZZ, -0.41 for its cancer drug, zanidatamab, which is currently being tested as a treatment for some HER2-expressing cancers. Jazz will pay Zymeworks 50 million upfront. 